Introduction
============

Endometriosis manifests as ectopic endometrial cells outside the uterus. It is an intractable disease that causes infertility, dysmenorrhea and pelvic pain. Endometriosis occurs in 10% of women of childbearing age. Notably, the incidence of endometriosis has been rising in recent years ([@b1-etm-0-0-3110]). The pathogenesis of endometriosis remains to be elucidated.

Published reports indicate that endometriosis is a polygenic/multifactorial disease caused by interactions between multiple genes and the environment ([@b2-etm-0-0-3110],[@b3-etm-0-0-3110]). In particular, a correlation has been identified between endometriosis and exposure to environmental toxins such as dioxin ([@b4-etm-0-0-3110]); dioxin and dioxin-like compounds have been implicated in the development of endometriosis ([@b5-etm-0-0-3110],[@b6-etm-0-0-3110]).

The phase II conjugation enzymes usually function to inactivate environmental toxins. Among these, glutathione S-transferase (GST) may be critical for the detoxification of dioxins. Human GSTs are classified into two distinct categories: Soluble or cytosolic and membrane-bound microsomal. The soluble or cytosolic GSTs are subdivided into seven families named α, µ, ω, π, σ, θ and ζ ([@b7-etm-0-0-3110]). Genes in several of these families are polymorphic, including: *GSTA2* in the α family, *GSTM1* and *GSTM3* in the µ family, *GSTP1* in the π family, *GSTO*, *GSTT1*, and *GSTT2* in the θ family, and *GSTZ1* in the ζ family. Heritable allelic differences in *GSTM1*, *GSTM3*, *GSTT1* and *GSTP1* may have marked relevance for individual susceptibility to disease.

*GSTM1* and *GSTT1* are two candidate genes that may play an important role in the development of endometriosis. *GSTM1* and *GSTT1* are located on chromosomes 1p13.3 and 22q11.23, respectively. They are critical in the detoxification of the products of oxidative stress produced during the repair of the ovarian epithelium. *GSTM1* and *GSTT1* null alleles have reduced enzyme activity, a state that may contribute to inefficient detoxification of intermediates produced during stress. This may increase damage to various host genes and contribute to the pathogenesis of endometriosis ([@b8-etm-0-0-3110],[@b9-etm-0-0-3110]).

A meta-analysis summarizing the literature up to the year 2005 suggested that the *GSTT1* null genotype, but not the *GSTM1* null genotype, was associated with an increased risk for endometriosis ([@b7-etm-0-0-3110]). In the years since 2005, additional reports investigating this topic have been published. The objective of the present study was to update the existing meta-analysis and reevaluate the possible associations between *GSTM1*, *GSTT1* and combined *GSTM1*/*GSTT1* (null genotype vs. wild-type) gene polymorphisms and susceptibility to endometriosis.

Materials and methods
=====================

### Searches

For this systematic review and meta-analysis, PubMed (from January 1996 to January 2014), Embase (from January 1996 to January 2014), Chinese BioMedical Literature database (from January 1996 to January 2014) and Google Scholar (from January 1996 to January 2014) were searched. The following keywords were used: 'endometriosis', 'polymorphisms', 'glutathione S-transferases', '*GSTM1*' and '*GSTT1*' or their combinations.

Reference lists from articles identified by the electronic search were searched by hand. This process was performed iteratively until no additional articles could be identified.

### Inclusion and exclusion criteria

Articles published in English or Chinese were included if they reported quantitative outcomes from case-control genetic association studies on *GSTM1*, *GSTT1* or combined *GSTM1*/*GSTT1* (null genotype vs. wild-type) gene polymorphisms and endometriosis versus non-endometriosis or healthy controls.

Studies were excluded if they were case reports, case-only studies, letters, reviews or meta-analyses; included subjects who were related; included cases of adenomyosis, which has unknown etiology ([@b10-etm-0-0-3110]); reported insufficient data; or were duplicate studies.

### Selection of studies

Two reviewers (XYX and ZSJ) independently examined titles and abstracts to select eligible studies. Records were removed that were ongoing or unpublished studies, or were published as abstracts or conference proceedings. Where data sets were overlapping or duplicated, only the most recent information was included. The full text of potentially relevant studies was retrieved. Two reviewers (XYX and HJG) independently examined the full text records to determine which studies met the inclusion criteria. Disagreement about the selection of studies was resolved by discussion and consensus.

### Data extraction and management

Two reviewers (XYX and ZSJ) independently extracted data from eligible studies including the first author\'s last name, publication year, study location, ethnicity, matching variability, diagnostic criteria, stages of disease, source of controls, numbers of cases and controls, and numbers and/or percentages of null genotypes. Disagreement about data extraction was resolved by discussion and consensus.

### Assessment of quality of evidence in included studies

Two reviewers (YYL and HJG) independently assessed quality of evidence in the included studies using the 9-star Newcastle-Ottawa Scale, which considers selection, comparability and outcome evaluation criteria.

### Assessment of heterogeneity

Heterogeneity was assessed using the χ2 test and I2 test. The I2 statistic was interpreted as follows: I2=0--40%, heterogeneity may not be important; I2= 30--60%, heterogeneity may be moderate; I2=50--90%, heterogeneity may be substantial; and I2=75--100%, considerable heterogeneity ([@b11-etm-0-0-3110]). If heterogeneity was present, meta-regression was used to find the source.

### Assessment of reporting biases

A funnel plot of effect estimates against their standard errors (SEs) was created to assess possible reporting bias between studies. Funnel plot asymmetry was assessed using Egger\'s linear regression test and Begg\'s rank correlation test; P\<0.05 suggested publication bias.

### GSTM1/GSTT1 and risk for endometriosis

Two reviewers (XYX and HJG) independently combined data from trials using a fixed-effect model (DerSimonian and Laird method) when there was no significant heterogeneity in populations (I2\<50%) and a random-effect model (Mantel-Haenszel method) when there was considerable heterogeneity. Variables were synthesized using odds ratios (ORs). A P-value of 0.05 was used as the cut-off value to determine statistical significance, and data are presented as the estimated OR with 95% confidence intervals (CIs). All statistical analyses were performed using STATA software, version 12.0 (StataCorp, College Station, TX, USA). Inconsistencies in data analysis were resolved through consensus and discussion with a third reviewer (ZSJ).

### Sensitivity and subgroup analyses

Sensitivity analyses were performed to explore the impact of excluding outlying results. Subgroup analyses were performed by stratifying patients according to ethnicity (Caucasian, Asian or mixed), characteristics of controls (hospital patients or healthy individuals), and quality of evidence (high-quality or low-quality).

Results
=======

### Screening and selection

The searches identified 120 articles. Titles and abstracts were screened, and 36 studies were identified as potentially eligible for inclusion. The full text articles for these studies were retrieved. Following analysis of the full text articles, four studies were excluded and 32 studies were found to be eligible for inclusion according to the criteria used for considering studies in this review ([Fig. 1](#f1-etm-0-0-3110){ref-type="fig"}).

### Included studies

The characteristics of the included studies are shown in [Table I](#tI-etm-0-0-3110){ref-type="table"}. There were 32 case-control genetic association studies involving 3,990 cases of endometriosis and 4,625 controls. One publication addressed two groups of subjects with different ethnicities and was considered as two case-control genetic association studies ([@b12-etm-0-0-3110]); thus, the total number of studies was considered to be 33. Studies included data relevant to the *GSTM1* genotype, *GSTT1* genotype or the combined *GSTM1*/*GSTT1* genotype. Of the 32 eligible studies, 20 were conducted in Asia ([@b12-etm-0-0-3110]--[@b31-etm-0-0-3110]), eight in Europe ([@b32-etm-0-0-3110]--[@b39-etm-0-0-3110]), two in North America ([@b40-etm-0-0-3110],[@b41-etm-0-0-3110]), and two in South America ([@b42-etm-0-0-3110],[@b43-etm-0-0-3110]). The evidence reported in 23 studies was identified as high-quality, and that in 10 studies was identified as low-quality.

### Excluded studies

Of the 36 studies that were relevant to the *GSTM1*/*GSTT1* genotype and endometriosis, four were excluded. Of these, three were duplicates ([@b13-etm-0-0-3110],[@b14-etm-0-0-3110],[@b32-etm-0-0-3110]), and one included subjects who were related ([@b44-etm-0-0-3110]).

### GSTM1/GSTT1 and risk for endometriosis

#### GSTM1genotype

Data reporting on the *GSTM1* gene polymorphism are described in 33 case-control studies (3,990 cases of endometriosis and 4,625 controls). The meta-analysis demonstrated that there was a significant association between the *GSTM1* null genotype and an increased risk for endometriosis (OR=1.56; 95% CI: 1.25--1.95; P\<0.0001; [Fig. 2A](#f2-etm-0-0-3110){ref-type="fig"}).

Subgroup analyses stratified by ethnicity (Caucasian: OR=1.599; 95% CI: 1.205--2.122; P=0.001; Asian: OR=1.772; 95% CI: 1.242--2.528, P=0.002), source of controls (hospital patients: OR=1.561; 95% CI: 1.151--2.117; P=0.004; healthy individuals: OR=1.569; 95% CI: 1.131--2.176; P=0.007), and quality of evidence (high-quality: OR=1.563; 95% CI: 1.253--1.949; P\<0.0001) confirmed this finding.

Subgroup analysis stratified for mixed ethnicity (two case control studies involving 111 cases of endometriosis and 78 controls) demonstrated a significant association between the *GSTM1* null genotype and a decreased risk for endometriosis (OR=0.404; 95% CI: 0.219--0.745; P=0.004; [Table II](#tII-etm-0-0-3110){ref-type="table"}). Compared with individual Caucasian and Asian populations, the difference was statistically significant (P\<0.001; data shown in [Table III](#tIII-etm-0-0-3110){ref-type="table"}).

#### GSTT1 genotype

Data reporting on the *GSTT1* gene polymorphism are described in 18 case-control studies (2,371 cases of endometriosis and 2,490 controls). The meta-analysis demonstrated a significant association between the *GSTT1* null genotype and an increased risk for endometriosis (OR=1.31; 95% CI: 1.02--1.68; P=0.037; [Fig. 2B](#f2-etm-0-0-3110){ref-type="fig"}).

Subgroup analysis stratified by ethnicity demonstrated a significant association between the *GSTT1* null genotype and an increased risk for endometriosis among Asians (OR=1.573; 95% CI: 1.186--2.085; P=0.002), but not among Caucasians (OR=1.124; 95% CI: 0.745--1.697; P=0.577).

Subgroup analyses stratified by the source of controls found no significant association between the *GSTT1* null genotype and an increased risk for endometriosis among hospital-based studies (OR=1.284; 95% CI: 0.963--1.712; P=0.089) or among healthy individuals (OR=1.315; 95% CI: 0.767--2.254; P=0.320).

Subgroup analyses stratified by quality of evidence demonstrated a significant association between the *GSTT1* null genotype and an increased risk for endometriosis among studies considered high-quality evidence (OR=1.376; 95% CI: 1.020--1.858; P=0.037), but not among studies considered low-quality evidence (OR=1.121, 95% CI: 0.646--1.944; P=0.684; [Table II](#tII-etm-0-0-3110){ref-type="table"}).

#### Combined GSTM1/GSTT1 genotype

Data reporting on the combined *GSTM1*/*GSTT1* gene polymorphism are described in eight case-control studies (1,083 cases of endometriosis and 1,222 controls). The meta-analysis demonstrated a significant association between the combined *GSTM1*/*GSTT1* null genotype and an increased risk for endometriosis (OR=1.68, 95% CI: 1.29--2.17; P\<0.0001; [Fig. 2C](#f2-etm-0-0-3110){ref-type="fig"}).

This association was unchanged by subgroup analyses stratified by source of controls (hospital-based studies: OR=1.797; 95% CI: 1.081--2.989; P=0.024; healthy individuals: OR=1.657; 95% CI: 1.085--2.532; P=0.001) or quality of evidence (high-quality evidence: OR=1.753; 95% CI: 1.265--2.430; P=0.001; low-quality evidence: OR=1.542; 95% CI: 1.009--2.356, P=0.045; [Table II](#tII-etm-0-0-3110){ref-type="table"}).

Subgroup analysis stratified by ethnicity demonstrated a significant association between the combined *GSTM1*/*GSTT1* null genotype and an increased risk for endometriosis among Asian populations (OR=1.898; 95% CI: 1.404--2.565; P\<0.001), but not among Caucasian populations (OR=1.185; 95% CI: 0.717--1.961; P=0.508).

#### Publication bias

Visual inspection of a Funnel plot, Egger\'s test and Begg\'s rank correlation test revealed no significant publication bias for the *GSTM1*, *GSTT1* and combined *GSTM1*/*GSTT1* studies ([Fig. 3](#f3-etm-0-0-3110){ref-type="fig"}; [Table IV](#tIV-etm-0-0-3110){ref-type="table"}).

#### Heterogeneity analysis

There was evidence of significant heterogeneity (I2\>50%) between studies of *GSTM1* and *GSTT1*, and those used in subgroup analyses, although not among studies of *GSTM1*/*GSTT1* combined ([Table IV](#tIV-etm-0-0-3110){ref-type="table"}). Therefore, the random-effect model was used in all analyses with the exception of the analysis of combined *GSTM1*/*GSTT1* gene polymorphisms. For the *GSTM1* and *GSTT1* gene polymorphisms, a meta-regression was conducted in which publication year, ethnicity, source of controls, sample size, and quality of evidence were covariates. All the covariates were entered into the meta-regression model simultaneously, and the covariates that had the highest P-values were omitted one at a time in order to identify any sources of heterogeneity among them. However, the meta-regression analysis did not identify any of these covariates as a significant source of heterogeneity ([Figs. 4](#f4-etm-0-0-3110){ref-type="fig"} and [5](#f5-etm-0-0-3110){ref-type="fig"}).

#### Sensitivity analysis

To explore the effects of individual studies on the pooled OR estimates, a sensitivity analysis was performed, with the omission of one study at a time. The OR estimates for the *GSTM1* polymorphism were not notably altered ([Fig. 6A](#f6-etm-0-0-3110){ref-type="fig"}). The OR estimates for the *GSTT1* and combined *GSTM1*/*GSTT1* polymorphisms were altered when studies were excluded ([Fig. 6B and C](#f6-etm-0-0-3110){ref-type="fig"}).

Discussion
==========

In the present study, a meta-analysis of data from 33 studies was conducted to examine the associations between the *GSTM1*, *GSTT1* and combined *GSTM1*/*GSTT1* null genotypes and susceptibility to endometriosis. The risk for endometriosis was significantly increased in the presence of the *GSTM1*, *GSTT1* and combined *GSTM1*/*GSTT1* null genotypes compared with the wild-type. Subgroup analyses stratified by ethnicity, source of controls and quality of evidence confirmed this finding among several subgroups, but particularly among studies considered high-quality evidence. Notably, among patients of mixed ethnicity, the *GSTM1* null genotype was significantly associated with a decreased risk for endometriosis compared with the wild-type.

A similar meta-analysis of 23 studies performed in 2005 demonstrated an increased risk for endometriosis in women with the *GSTT1* null genotype ([@b8-etm-0-0-3110]). However, the authors requested that their findings be interpreted with caution as asymmetry in the funnel plot was evident, which was likely due to publication bias ([@b8-etm-0-0-3110]). This previous study did not include subgroup analyses or an evaluation of the combined *GSTM1*/*GSTT1* null genotype-endometriosis association.

Previous meta-analyses have found that the *GSTM1*/*GSTT1* gene polymorphism is associated with cervical cancer ([@b45-etm-0-0-3110]), breast cancer ([@b46-etm-0-0-3110]), bladder cancer ([@b47-etm-0-0-3110]), gastric cancer ([@b48-etm-0-0-3110],[@b49-etm-0-0-3110]) and acute leukemia ([@b50-etm-0-0-3110]). In accordance with the observations of the present study, several studies have shown that the *GSTM1* (OR=32.6, 95% CI: 15.07--70.32, P\<0.0001) ([@b18-etm-0-0-3110]) and *GSTT1* (OR\>3; P\<0.0001) null genotypes ([@b12-etm-0-0-3110],[@b16-etm-0-0-3110]) are associated with an increased risk for endometriosis. However, other reports suggest the *GSTM1* (OR=0.21, 95% CI: 0.09--0.52, P\<0.0001; OR=0.35, 95% CI: 0.15--0.83, P\<0.0001) ([@b40-etm-0-0-3110],[@b43-etm-0-0-3110]), *GSTT1* (OR≥5; P\<0.0001) ([@b16-etm-0-0-3110]) and combined *GSTM1*/*GSTT1* (OR=0.38; P\<0.001) ([@b17-etm-0-0-3110]) null genotypes are associated with a decreased risk for endometriosis. These divergent results may be explained by differences in *GSTM1*/*GSTT1* null genotype frequencies and study locations. The frequency of the *GSTM1*/*GSTT1* null genotype may vary from 10 to 65% depending on the region and population studied ([@b51-etm-0-0-3110]). Different study locations may introduce confounding variables associated with variations in lifestyles and exposures to toxic substances of the study populations.

The results of the present study must be interpreted with caution due to the presence of substantial heterogeneity. Among analyses of the studies of *GSTM1* and *GSTT1*, the cause of heterogeneity remains unclear, despite meta-regression analyses being conducted. Among the analyses of combined *GSTM1*/*GSTT1* studies, subgroup and sensitivity analyses suggested that studies that included patients with advanced stage endometriosis caused most of the variability. Publication bias was unlikely to have influenced the findings.

In addition to the heterogeneity, there were several limitations to this study. Firstly, the composition of the endometriosis patient and control populations varied between studies. For instance, some studies included only patients with advanced endometriosis ([@b17-etm-0-0-3110]--[@b20-etm-0-0-3110],[@b22-etm-0-0-3110],[@b27-etm-0-0-3110],[@b35-etm-0-0-3110]), while control populations consisted of a mixture of infertile ([@b29-etm-0-0-3110]), postmenopausal ([@b43-etm-0-0-3110]) and premenopausal ([@b18-etm-0-0-3110],[@b35-etm-0-0-3110]) women, and newborn babies that had not been exposed to the environment ([@b17-etm-0-0-3110]). Furthermore, patients and controls were not always accurately matched by age or environmental exposures. Secondly, gene-gene or gene-environment interactions may jointly increase the risk for endometriosis; therefore, different lifestyle and environmental factors may contribute to differential genotypic frequencies in cases and controls. Attempts were made to mitigate inaccuracies associated with this limitation through a subgroup analysis stratified according to ethnicity. Thirdly, this study was based on published articles. As a positive result is more likely to be published, publication bias is an inherent limitation of all meta-analyses irrespective of the outcomes of the Egger\'s linear regression test and Begg\'s rank correlation test.

In conclusion, the present meta-analysis shows the *GSTM1*, *GSTT1* and combined *GSTM1*/*GSTT1* null genotypes are likely associated with increased susceptibility to endometriosis. These data are in contrast to those reported previously. Therefore, further studies reporting higher quality evidence are necessary to verify these conclusions.
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![PRISMA 2009 flow diagram showing the article screening and selection process. Using the search strategy, 120 articles were identified by the initial search, and 36 required further assessment. Finally, 32 articles were included in this review, one of which was considered as two studies. *GSTM1*, glutathione S-transferase µ1; *GSTT1*, glutathione S-transferase θ1.](etm-11-05-1633-g00){#f1-etm-0-0-3110}

![Association between *GSTM1*, *GSTT1* and the combined *GSTM1*/*GSTT1* null genotypes and susceptibility to endometriosis. (A) A total of 33 studies described the association between the *GSTM1* null genotype and susceptibility to endometriosis \[odds ratio (OR)=1.56; 95% confidence interval (CI): 1.25--1.95; P\<0.0001\]; and (B) 18 studies described the association between the *GSTT1* null genotype and susceptibility to endometriosis (OR=1.31; 95% CI: 1.02--1.68; P=0.037). GSTM1, glutathione S-transferase μ1;. GSTT1, glutathione S-transferase θ1.](etm-11-05-1633-g01){#f2-etm-0-0-3110}

![Continued. (C) Eight studies described the association between the combined *GSTM1/GSTT1* null genotypes and susceptibility to endometriosis \[odds ratio (OR)=1.68; 95% confidence interval (CI): 1.29--2.17; P\<0.0001\]. *GSTM1*, glutathione S-transferase µ1;. *GSTT1*, glutathione S-transferase θ1.](etm-11-05-1633-g02){#f2a-etm-0-0-3110}

![Assessment of publication bias for studies on (A) *GSTM1*, (B) *GSTT1* and (C) combined *GSTM1/GSTT1* genotypes. GSTM1, glutathione S-transferase µ1;. *GSTT1*, glutathione S-transferase θ1.](etm-11-05-1633-g03){#f3-etm-0-0-3110}

![Meta-regression for *GSTM1* studies, with publication year, ethnicity, source of controls, sample size, and quality of evidence as covariates. All covariates were entered into the meta-regression model simultaneously, and the covariates with the highest P-values were omitted one at a time to identify sources of heterogeneity. The meta-regression did not identify any of these covariates as a significant source of heterogeneity. Variables were omitted in the following order: Size (A→B), source (B→C), publication year (C→D), ethnicity (D→E). *GSTM1*, glutathione S-transferase µ1.](etm-11-05-1633-g04){#f4-etm-0-0-3110}

![Meta-regression for *GSTT1* studies, with publication year, ethnicity, source of controls, sample size, and quality of evidence as covariates. All covariates were entered into the meta-regression model simultaneously, and covariates with the highest P-values were omitted one at a time to identify sources of heterogeneity. Meta-regression identified publication year as a significant source of heterogeneity (P=0.048), but after omitting this covariate heterogeneity remained substantial (I^2^=67.21%) Variables were omitted in the order: Source (A→B), quality (B→C), ethnicity (C→D), size (D→E). *GSTT1*, glutathione S-transferase θ1](etm-11-05-1633-g05){#f5-etm-0-0-3110}

![Sensitivity analyses investigating the association between the (A) *GSTM1*, (B) *GSTT1* and (C) combined *GSTM1/GSTT1* null genotypes and susceptibility to endometriosis; one study was omitted at a time. *GSTM1*, glutathione S-transferase µ1;. *GSTT1*, glutathione S-transferase θ1.](etm-11-05-1633-g06){#f6-etm-0-0-3110}

###### 

Characteristics of included studies on the *GSTM1, GSTT1* and combined *GSTM1/GSTT1* gene polymorphisms.

                                                                                 *GSTM1* (n)   *GSTT1* (n)   *GSTM1+GSTT1* (n)                               
  -------------------- ----------- ---------------- --------------------- ------ ------------- ------------- ------------------- --------- -------- -------- -----------------------
  Baranov, 1996        Caucasian   Russia           Healthy individuals   Low    42/34         67/26                                                         ([@b33-etm-0-0-3110])
  Baranova, 1999       Caucasian   Russia, France   Hospital patients     High   65/50         72/33         65/13               72/7                        ([@b32-etm-0-0-3110])
  Baranov, 1999        Caucasian   Russia           Healthy individuals   Low    150/88        99/42                                                         ([@b34-etm-0-0-3110])
  Hadfield, 2001       Caucasian   UK               Hospital patients     High   132/59        52/27         116/29              50/14                       ([@b35-etm-0-0-3110])
  Baxter, 2001         Caucasian   England          Healthy individuals   High   84/40         219/107                                                       ([@b36-etm-0-0-3110])
  Bischoff, 2002       Caucasian   USA              Hospital patients     Low    62/13         36/20                                                         ([@b40-etm-0-0-3110])
  Ivaschenko, 2003     Caucasian   Russia           Hospital patients     High   74/42         40/17         74/27               40/6      74/16    40/2     ([@b37-etm-0-0-3110])
  Arvanitis, 2003      Caucasian   Greece           Healthy individuals   High   275/161       346/181       275/24              346/31    275/11   346/16   ([@b38-etm-0-0-3110])
  Peng, 2003           Asian       China            Hospital patients     High   76/50         80/37                                                         ([@b15-etm-0-0-3110])
  Lin, 2003            Asian       China            Hospital patients     High   68/49         28/12         68/53               28/9                        ([@b16-etm-0-0-3110])
  Morizane, 2004       Asian       Japan            Healthy individuals   Low    108/57        173/89        108/52              173/71    108/30   173/43   ([@b17-etm-0-0-3110])
  Hsieh, 2004          Asian       China            Hospital patients     High   150/95        159/8                                                         ([@b18-etm-0-0-3110])
  De Carvalho, 2004    Mixed       Brazil           Hospital patients     Low    61/21         32/17                                                         ([@b42-etm-0-0-3110])
  Ding, 2004           Asian       China            Healthy individuals   High   80/46         105/55        80/59               105/47    80/34    105/24   ([@b12-etm-0-0-3110])
  Ding, 2004           Asian       China            Healthy individuals   High   41/21         107/57        41/15               107/32    41/10    107/14   ([@b12-etm-0-0-3110])
  Babu, 2005           Caucasian   India            Hospital patients     High   310/121       215/64        310/42              215/34    310/14   215/11   ([@b19-etm-0-0-3110])
  Hur, 2005            Asian       Korea            Hospital patients     Low    194/112       259/145       194/104             259/125                     ([@b20-etm-0-0-3110])
  Aban, 2007           Caucasian   Turkey           Hospital patients     High   150/88        150/65        150/59              150/44                      ([@b21-etm-0-0-3110])
  Chang, 2007          Asian       China            Hospital patients     High   74/48         65/30         74/46               65/32     74/27    65/13    ([@b30-etm-0-0-3110])
  Kim, 2007            Asian       Korea            Hospital patients     High   316/183       256/146       316/178             256/124                     ([@b22-etm-0-0-3110])
  Rozati, 2009         Caucasian   India            Hospital patients     High   97/26         102/15                                                        ([@b13-etm-0-0-3110])
  Yang, 2009           Asian       China            Hospital patients     Low    216/134       216/100                                                       ([@b14-etm-0-0-3110])
  Cao, 2009            Asian       China            Hospital patients     High   51/33         102/61        51/22               102/39                      ([@b23-etm-0-0-3110])
  Wu, 2009             Asian       China            Hospital patients     High   96/63         85/40                                                         ([@b24-etm-0-0-3110])
  Huang, 2010          Asian       China            Hospital patients     High   28/12         29/10                                                         ([@b25-etm-0-0-3110])
  Trabert, 2011        Caucasian   USA              Healthy individuals   High   254/137       567/268                                                       ([@b41-etm-0-0-3110])
  Hosseinzadeh, 2011   Caucasian   Iran             Healthy individuals   High   120/87        200/80                                                        ([@b26-etm-0-0-3110])
  Wu, 2012             Asian       China            Healthy individuals   Low    121/57        171/52        121/40              171/33    121/23   171/15   ([@b27-etm-0-0-3110])
  Seifati, 2012        Caucasian   Iran             Hospital patients     High   101/51        142/74                                                        ([@b28-etm-0-0-3110])
  Vichi, 2012          Caucasian   Italy            Hospital patients     High   181/104       162/85        181/20              162/32                      ([@b39-etm-0-0-3110])
  Matsuzaka, 2012      Asian       Japan            Hospital patients     High   97/43         143/67        97/38               143/56                      ([@b29-etm-0-0-3110])
  Frare, 2013          Mixed       Brazil           Healthy individuals   Low    50/25         46/34         50/16               46/27                       ([@b43-etm-0-0-3110])
  Sachan, 2013         Caucasian   Iran             Healthy people        Low    66/27         100/16                                                        ([@b31-etm-0-0-3110])

Null genotype vs. wild type gene polymorphisms and susceptibility to endometriosis. GSTM1, glutathione S-transferase µ1; GSTT1, glutathione S-transferase θ1.

###### 

Meta-analysis of the association between *GSTM1*, *GSTT1* and combined *GSTM1*/*GSTT1* (null genotype vs. wild-type) gene polymorphisms and susceptibility to endometriosis.

  Group                               No. of studies   No. of subjects (cases/controls)   OR \[95%CI\]             P-value
  ----------------------------------- ---------------- ---------------------------------- ------------------------ ---------
  Total studies                                                                                                    
    *GSTM1* genotype                  33               3,990/4,625                        1.563 \[1.253--1.949\]   \<0.001
    *GSTT1* genotype                  18               2,371/2,490                        1.345 \[1.044--1.733\]   0.022
    *GSTM1*+*GSTT1* genotype            8              1,083/1,222                        1.672 \[1.291--2.166\]   0.005
  Caucasian                                                                                                        
    *GSTM1* genotype                  16               2,163/2,569                        1.599 \[1.205--2.122\]   0.001
    *GSTT1* genotype                    7              1,171/1,035                        1.124 \[0.745--1.697\]   0.577
    *GSTM1*+*GSTT1* genotype            3              659/601                            1.185 \[0.717--1.961\]   0.508
  Asian                                                                                                            
    *GSTM1* genotype                  15               1,716/1,978                        1.772 \[1.242--2.528\]   0.002
    *GSTT1* genotype                  10               1,150/1,409                        1.573 \[1.186--2.085\]   0.002
    *GSTM1*+*GSTT1* genotype            5              424/621                            1.898 \[1.404--2.565\]   \<0.001
  Mixed                                                                                                            
    *GSTM1* genotype                    2              111/78                             0.404 \[0.219--0.745\]   0.004
    *GSTT1* genotype                    1              50/46                                                       
    *GSTM1*+*GSTT1* genotype            0                                                                          
  Controls from hospital patients                                                                                  
    *GSTM1* genotype                  21               2,599/2,425                        1.561 \[1.151--2.117\]   0.004
    *GSTT1* genotype                  12               1,696/1,542                        1.284 \[0.963--1.712\]   0.089
    *GSTM1*+*GSTT1* genotype            3              458/320                            1.797 \[1.081--2.989\]   0.024
  Controls from healthy individuals                                                                                
    *GSTM1* genotype                  12               1,391/2,200                        1.569 \[1.131--2.176\]   0.007
    *GSTT1* genotype                    6              675/948                            1.315 \[0.767--2.254\]   0.320
    *GSTM1*+*GSTT1* genotype            5              625/902                            1.657 \[1.085--2.532\]   0.001
  High quality                                                                                                     
    *GSTM1* genotype                  23               2,920/3,426                        1.563 \[1.253--1.949\]   \<0.001
    *GSTT1* genotype                  14               1,898/1,841                        1.376 \[1.020--1.858\]   0.037
    *GSTM1*+*GSTT1* genotype            6              854/878                            1.753 \[1.265--2.430\]   0.001
  Low quality                                                                                                      
    *GSTM1* genotype                  10               1,070/1,199                        1.259 \[0.785--2.020\]   0.340
    *GSTT1* genotype                    4              473/649                            1.121 \[0.646--1.944\]   0.684
    *GSTM1*+*GSTT1* genotype            2              229/344                            1.542 \[1.009--2.356\]   0.045

OR, odds ratio; CI, confidence interval; *GSTM1*, glutathione S-transferase µ1; *GSTT1*, glutathione S-transferase θ1.

###### 

Comparisons of subgroup analyses for *GSTM1*, *GSTT1* and combined *GSTM1/GSTT1* studies.

  A, Analysis of the *GSTM1* gene                                                         
  ------------------------------------ ------------ ------------------- -------- -------- -------------------------------------------------------
  Ethnicity                                                                      3.245    0.72^[a](#tfn3-etm-0-0-3110){ref-type="table-fn"}^
    Caucasian                          Cases        1,128               1,035             
                                         Controls   1,120               1,449             
    Asian                              Cases        1,003               713               
                                         Controls   909                 1,069             
    Mixed                              Cases        46                  65       18.737   \<0.001^[b](#tfn4-etm-0-0-3110){ref-type="table-fn"}^
                                       Controls     51                  27       23.467   \<0.001^[c](#tfn5-etm-0-0-3110){ref-type="table-fn"}^
  Source of controls                                                             0.130    0.718
    Hospital patients                  Cases        1,397               1,202             
                                       Controls     1,073               1,352             
    Healthy individuals                Cases        780                 611               
                                       Controls     1,007               1,193             
  Quality                                                                        0.825    0.364
    High quality                       Cases        1,609               1,311             
                                       Controls     1,539               1,887             
    Low quality                        Cases        568                 502               
                                       Controls     541                 658               
                                                                                          
  B, Analysis of the *GSTT1* gene                                                         
                                                                                          
                                                    *GSTT1* (n)                           
                                                                                          
  Subgroup                             Subjects     Null                Normal   χ^2^     P-value
                                                                                          
  Ethnicity                                                                      6.766    0.009
    Caucasian                          Cases        214                 957               
                                       Controls     168                 867               
    Asian                              Cases        607                 543               
                                       Controls     568                 841               
  Source of controls                                                             0.638    0.425
    Hospital patients                  Cases        631                 1,065             
                                       Controls     522                 1,020             
    Healthy individuals                Cases        206                 469               
                                       Controls     241                 707               
  Quality                                                                        0.062    0.803
    High quality                       Cases        625                 1,273             
                                         Controls   507                 1,334             
    Low quality                        Cases        212                 261               
                                       Controls     256                 393               
                                                                                          
  C, Analysis of *GSTM1+GSTT1* genes                                                      
                                                                                          
                                                    *GSTM1+GSTT1* (n)                     
                                                                                          
  Subgroup                             Subjects     Null                Normal   χ^2^     P-value
                                                                                          
  Ethnicity                                                                      7.642    0.006
    Caucasian                          Cases        41                  618               
                                       Controls     29                  572               
    Asian                              Cases        124                 300               
                                       Controls     109                 152               
  Source of controls                                                             0.091    0.763
    Hospital patients                  Cases        57                  401               
                                       Controls     26                  294               
    Healthy individuals                Cases        108                 517               
                                       Controls     112                 790               
  Quality                                                                        0.022    0.882
    High quality                       Cases        112                 542               
                                       Controls     80                  598               
    Low quality                        Cases        53                  176               
                                       Controls     58                  286               

Caucasians vs..Asians

Caucasians vs. mixed

Asians vs. mixed.

###### 

Heterogeneity and publication bias of *GSTM1*, *GSTT1* and combined *GSTM1*/*GSTT1* studies.

                                      Heterogeneity   Publication bias (P-value)             
  ----------------------------------- --------------- ---------------------------- --------- -------
  Total studies                                                                              
    *GSTM1* genotype                  81.8            \<0.001                      0.313     0.412
    *GSTT1* genotype                  69.9            \<0.001                      0.557     0.705
    *GSTM1*+*GSTT1* genotype          44.7            0.081                        0.170     1.000
  Caucasian                                                                                  
    *GSTM1* genotype                  79.2            \<0.001                      0.454     0.322
    *GSTT1* genotype                  64.7            0.009                        0.339     0.764
    *GSTM1*+*GSTT1* genotype          58.5            0.090                        0.021     0.296
  Asian                                                                                      
    *GSTM1* genotype                  83.8            \<0.001                      0.098     0.083
    *GSTT1* genotype                  62.4            0.004                        0.160     0.210
    *GSTM1*+*GSTT1* genotype          13.6            0.081                        0.340     0.806
  Mixed                                                                                      
    *GSTM1* genotype                  0.0             0.664                        \<0.001   0.317
  Controls from hospital patients                                                            
    *GSTM1* genotype                  83.6            \<0.001                      0.390     0.506
    *GSTT1* genotype                  65.9            0.001                        0.335     0.451
    *GSTM1*+*GSTT1* genotype          62.2            0.071                        0.585     1.000
  Controls from healthy individuals                                                          
    *GSTM1* genotype                  79.4            \<0.001                      0.598     0.784
    *GSTT1* genotype                  78.4            \<0.001                      0.431     0.707
    *GSTM1*+*GSTT1* genotype          45.9            0.116                        0.531     1.000
  High quality                                                                               
    *GSTM1* genotype                  80.9            \<0.001                      0.042     0.068
    *GSTT1* genotype                  69.9            \<0.001                      0.530     0.189
    *GSTM1*+*GSTT1* genotype          49.0            0.081                        0.641     1.000
  Low quality                                                                                
    *GSTM1* genotype                  85.1            \<0.001                      0.788     0.516
    *GSTT1* genotype                  77.2            0.004                        0.347     1.000
    *GSTM1*+*GSTT1* genotype          62.9            0.101                                  

GSTM1, glutathione S-transferase µ1;. GSTT1, glutathione S-transferase θ1.

[^1]: Contributed equally
